Stem cell genes in androgen-independent prostate cancer

Cancer and Metastasis Reviews

Volumn 17, Issue 4, 1998, Pages 391-399

  Bui, Matthew ^a   Reiter, Robert E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hormone refractory; Molecular biology; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; TELOMERASE;

APOPTOSIS; BASAL CELL; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; HORMONAL REGULATION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STEM CELL;

EID: 0032795334     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006197923640     Document Type: Review

References (60)

1. Isaacs JT: Control of cell proliferation and cell death in the normal and neoplastic prostate: A stem cell model. In: Rodgers CH, Coffey DS, Cunha G, Grayhack JT, Hinman F, Horton R (eds), Benign Prostate Hyperplasia. Vol. II. pp 85-94. Bethesda. MD: NIH Publication No 87-2881, 1987
2. Bonkhoff H, Stein U, Aumuller G, Remberger K: Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 29: 261-7, 1996
3. Bonkhoff H: Role of the basal cells in premalignant changes of the human prostate: a stem cell concept for the development of prostate cancer. European Urology 30: 201-5, 1996
4. Liu AY, True LD, LaTray L, Nelson PS, Ellis WJ, Vessella RL, Lange PH, Hood L, van den Engh G: Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci USA 94: 10705-10, 1997
5. Aumuller G: Morphologic and endocrine aspects of prostatic functions. Prostate 4: 195-214, 1983
6. Magi GC, Loda M: Molecular events in the early phases of prostate carcinogenesis. Eur Urol 30: 167-76, 1996
7. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122: 552, 1988
8. Bonkhoff H, Remberger K: Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate. Virchows Arch A Pathol Anat Histopathol 422: 35-8, 1993
9. Bonkhoff H, Stein U, Remberger K: The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 24: 114-8, 1994
10. Isaacs JT, Coffey DS: Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 2: 33-50, 1989
11. English HF, Santen RJ, Isaacs JT: Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 11: 229-42, 1987
12. Evans GS, Chandler JA: Cell proliferation studies in the rat prostate: II. The effects of castration and androgen-induced regeneration upon basal and secretory cell proliferation. Prostate 11: 339-51, 1987
13. Bonkhoff H, Stein U, Remberger K: Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 25: 42-6, 1994
14. Bonkhoff H: Role of the basal cells in premalignant changes of the human prostate: a stem cell concept for the development of prostate cancer. Eur Urol 30: 201-5, 1996
15. Bonkhoff H, Remberger K: Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model. Prostate 28: 98-106, 1996
16. Verhagen AP, Aalders TW, Ramaekers FC, Debruyne FM, Schalken JA: Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. Prostate 13: 25-38, 1988
17. Verhagen AP, Ramaekers FC, Aalders TW, Schaafsma HE, Debruyne FM, Schalken JA: Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res 52: 6182-7, 1992
18. Xue Y, Smedts F, Debruyne FM, de la Rosette JJ, Schalken JA: Identification of intermediate cell types by keratin expression in the developing human prostate (published erratum appears in Prostate 1998 May; 35(2): 156). Prostate 34: 292-301, 1998
19. Robinson EJ, Neal DE, Collins AT: Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate 37: 149-60, 1998
20. Nagle RB, Ahmann FR, McDaniel KM, Paquin ML, Clark VA, Celniker A: Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res 47: 281-6, 1987
21. De Marzo MA, Nelson WG, Meeker AK, Coffey DS: Stem cell features of benign and malignant prostate epithelial cells. J Urol 1998
22. Bonkhoff H, Stein U, Remberger K: Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 26: 167-170, 1995
23. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL: Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nature Medicine 3: 402-8, 1997
24. Hobisch A, Culig Z, Radmayr C, Bartsch G., Klocker H, Hittmair A: Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Research 55: 3068-72, 1995
25. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP: Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 152: 1-9, 1998
26. Kokontis JM, Hay N, Liao S: Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12: 941-53, 1998
27. Visakorpi T, Hyytinen E, Doivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP: In vivo amplification of the androgen receptor gene and progression of human prostate cancer: Nature Gen 9: 401-406, 1995
28. Tilley WD, Buchanan G, Hickey TE, Bentel JM: Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2: 277-285, 1996
29. Veldsholte J, Ris-Stalpers C, Kuiper G: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Com 173: 534-540, 1990
30. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, JW, M, Srivastava S: Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54: 2861-2864, 1994
31. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z: Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58: 4640-5, 1998
32. Steiner MS: Review of peptide growth factors in benign prostatic hyperplasia dn urological malignancies. Journal of Urology 153: 1085-1096, 1995
33. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM, Campbell ML: Expression of the proto-oncogene Bcl-2 in the prostate and association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992
34. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400, 1993
35. Lu QL, Abel P, Foster CS, and Lalani EN: Bcl-2: role in epithelial differentiation and oncogenesis. Human Pathol 27: 102-10, 1996
36. Stattin P, Damber JE, Karlberg L, Nordgren H, Bergh A: Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival. Urol Res 24: 257-264, 1996
37. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R: Overexpression or bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55: 4438-45, 1995
38. Meeker AK, Sommerfeld HJ, Coffey DS: Telomerase is activated in the prostate and seminal vesicles of the castrated rat. Endocrinology 137: 5743-6, 1996
39. Sommerfield HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS: Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 56: 218-223, 1996
40. Chung LW: The role of stromal-epithelial interaction in normal and malignant growth. Cancer Surveys 23: 33-42, 1995
41. Dorkin TJ, Neal DE: Basic science aspects of prostate cancer. Sem Canc Biol 8: 21-7, 1997
42. Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R: Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 3: 21-30, 1997
43. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenback AC, Chung L: c-met protooncogene expression in benign and malignant human prostate tissues. J Urol 154: 293-298, 1995
44. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-8, 1994
45. Pietrzkowski Z, Wernicke D, Poreu P, Jameson BA, Baserga R: Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor I. Cancer Res 52: 6447-51, 1992
46. Myers RB, Grizzle WE: Changes in biomarker expression in the development of prostatic adenocarcinoma. Biotech Histochem 72: 86-95, 1997
47. De Marzo MA, Meeker AK, Epstein JI, Coffey DS: Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 153: 911-9, 1998
48. Reiter RE, Magi-Galuzzi C, Hemmatti H, Sawyers C, Loda M, Witte ON: Two genes upregulated in androgen-independent prostate cancer are also selectively expressed in the basal cells of normal prostate epithelium. J Urol 157 (Supplement): 269A, 1997
49. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le BM, Loda M, Witte ON: Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 95: 1735-40, 1998
50. Myers RB, Srivastava S, Oelschlager DK, Grizzle WE: Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma (see comments). J Natl Cancer Inst 86: 1140-5, 1994
51. Yang Y, Hao J, Liu X, Dalkin B, Nagle RB: Differential expression of cytokeratin mRNA and protein in normal prostate, prostatic intraepithelial neoplasia, and invasive carcinoma. Am J Pathol 150: 693-704, 1997
52. McNeal JE, Haillot O, Yemoto C: Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. Prostate 27: 258-68, 1995
53. Magi GC, Xu X, Hlatky L, Hahnfeldt P, Kaplan T, Hsiao P, Chang C, Loda M: Heterogeneity of androgen receptor content in advanced prostate cancer. Modern Pathology 10: 839-45, 1997
54. Kadkol SS, Brody JR, Epstein JI, Kuhajda FP, Pastemack GR: Novel nuclear phosphoprotein pp32 is highly expressed in intermediate- and high-grade prostate cancer. Prostate 34: 231-7, 1998
55. Bonkhoff H: Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate (Supplement) 8: 18-22, 1998
56. Abrahamsson PA: Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate (Supplement) 6: 3-8, 1996
57. di SAP: Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer, 1992
58. Jiborn T, Bjartell A, Abrahamsson PA: Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 51: 585-9, 1998
59. Antica M, Wu L, Scollay R: Stem cell antigen 2 expression in adult and developing mice. Immunology letters 55: 47-51, 1997
60. Classon BJ, Cloverdale L: Mouse stem cell antigen Sca-2 is a member of the Ly-6 family of cell surface proteins. Proc Nat Ac Sci 91: 5296-5300, 1994